TD Cowen lowered the firm’s price target on Apellis (APLS) to $45 from $50 and keeps a Buy rating on the shares. The firm noted Q3 Syfovre sales of $151MM (0% Q/Q) were modestly below consensus (156MM) and management guided to steady but measured growth in future quarters.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $52 from $50 at Baird
- Apellis price target lowered to $45 from $52 at Citi
- Apellis price target lowered to $45 from $57 at H.C. Wainwright
- Apellis Pharmaceuticals Reports Strong Q3 2025 Earnings
- Apellis Pharmaceuticals: Strong Market Position and Growth Potential Amidst Challenges